Released Nov 14, 2023, after the close
10-Q filed Nov 14, 2023, 45 days after period end · 0001785530-23-000033
Q3 2023 · 10-Q
Revenue—
Net Income-$8.29M-$8.29M N/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.23-$0.23 N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$9,251,000N/M
Operating Cash Flowderived-$7,208,000N/M
Free Cash Flowderived-$7,429,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Net Income | -$8.29M | -$11.94M | -$13.76M | -$6.07M |
| EPS Diluted | -$0.23 | -$0.40 | -$0.51 | -$6.61 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR